European Parliament debate on embryonic stem cell research funding:
This article was originally published in Clinica
A lively debate has taken place at the European Parliament on the question of whether stem-cell research should be financed through EU funding. While there are still huge differences of opinion between the MEPs, the scientists and member states, the aim is to achieve an eventual compromise on many of the issues. The European Commission hopes to draw up a proposal for establishing guidelines for deciding on EU funding of research projects involving the use of human embryos and human embryonic stem cells. The EP'sdiscussion is pivotal to the future of medicine: if stem cells can cure some diseases, such as multiple sclerosis (where there has been great success in trials with mice), there will be a significant shift in the need for other interventions and treatments for such diseases in the future.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.